


# Polycythemia Vera

## TREATMENT FOR HIGH-RISK POLYCYTHEMIA VERA

Alessandro Maria **Vannucchi**, Paola **Guglielmelli**, Fabrizio **Pane**,  
Francesco **Passamonti**, Valerio **De Stefano**, Massimo **Breccia**, Elisabetta **Abruzzese**  
Francesca **Palandri**, Tiziano **Barbui**


# Treatment for High-Risk Polycythemia Vera



1. FDA/EMA Approved for the treatment of PV with no symptomatic splenomegaly  
 2. AIFA criteria for drug reimbursement as first-line include females with motherhood desire and individuals with previous episodes of NMSC

3. FDA/EMA Approved for the treatment of adult patients with PV resistant to or intolerant of Hydroxyurea  
 4. AIFA criteria for drug reimbursement only as second-line





Il presente documento è il prodotto finale del progetto *Clinical Assessment of resistance and Intolerance to Hydroxyurea as Criteria for Second-line Treatment in patients with Polycythemia Vera*, condotto nel corso del 2023 e 2024 dal Working Party GIMEMA sulle Neoplasie Mieloproliferative Croniche.

EXPERT PANEL

Alessandro Maria **Vannucchi** (coordinatore)

Paola **Guglielmelli** (referente di progetto)

Fabrizio **Pane**

Francesco **Passamonti**

Valerio **De Stefano**

Massimo **Breccia**

Elisabetta **Abruzzese**

Francesca **Palandri**

Tiziano **Barbui**

---

Questo progetto è stato realizzato con il supporto non condizionante di **AOP Health**.

